中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 457-460

Clinical management of chronic hepatitis B virus infection comorbid with metabolic dysfunction

DOI: 10.12449/JCH240304
  • 1.

    The Fourth Clinical Medical College of Zhejiang Chinese Medical University，Hangzhou 310053，China

  • 2.

    Department of Infectious Diseases & Hepatology，The Affiliated Hospital of Hangzhou Normal University，Hangzhou 310015，China

More Information
  • Corresponding author: SHI Junping， 20131004@hznu.edu.cn （ORCID： 0000-0001-9434-897X）
  • Received Date: 2024-01-10
  • Accepted Date: 2024-02-01
  • Published Date: 2024-03-20
    Abstract
  • With the rapid growth of metabolic dysfunction （MD） worldwide， there is also a gradual increase in the number of patients with chronic hepatitis B virus （HBV） infection and MD. Comorbidity with metabolic disorders such as hyperglycemia， hypertension， and dyslipidemia may increase the risk of adverse liver outcomes and cardiovascular events in patients with chronic HBV infection and affect the response to anti-HBV therapy. The standardized management of patients with chronic HBV infection and MD has become a challenge at present， and further in-depth research on the interaction between MD and HBV and targeted management strategies will help to optimize the clinical management of patients with chronic HBV infection.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    ALBERTI KG, ECKEL RH, GRUNDY SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity[J]. Circulation, 2009, 120( 16): 1640- 1645. DOI: 10.1161/CIRCULATIONAHA.109.192644.
    [2]
    ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
    [3]
    RINELLA ME, LAZARUS JV, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology, 2023, 78( 6): 1966- 1986. DOI: 10.1097/HEP.0000000000000520.
    [4]
    Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, et al. Expert recommendations on standardized diagnosis and treatment for fatty liver disease(2019 revised edition)[J]. J Clin Hepatol, 2019, 35( 11): 2426- 2430. DOI: 10.3969/j.issn.1001-5256.2019.11.007.

    中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝与酒精性肝病学组, 等. 脂肪性肝病诊疗规范化的专家建议(2019年修订版)[J]. 临床肝胆病杂志, 2019, 35( 11): 2426- 2430. DOI: 10.3969/j.issn.1001-5256.2019.11.007.
    [5]
    FAN JG, LI XY. NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures][J] Chin J Hepatol, 2023, 31( 8): 789- 792. DOI: 10.3760/cma.j.cn501113-20230809-00042.

    范建高, 李小英. NAFLD更名MAFLD、MASLD: 背景、异同、对策[J]. 中华肝脏病杂志, 2023, 31( 8): 789- 792. DOI: 10.3760/cma.j.cn501113-20230809-00042.
    [6]
    XIE J, WANG X, PAN D, et al. Ageing and non-liver comorbidities in population with chronic hepatitis B infection in the western pacific region from 1990 to 2019[J]. Front Physiol, 2023, 14: 1176113. DOI: 10.3389/fphys.2023.1176113.
    [7]
    WONG GL, WONG VW, YUEN BW, et al. An aging population of chronic hepatitis B with increasing comorbidities: A territory-wide study from 2000 to 2017[J]. Hepatology, 2020, 71( 2): 444- 455. DOI: 10.1002/hep.30833.
    [8]
    PAN XF, WANG L, PAN A. Epidemiology and determinants of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9( 6): 373- 392. DOI: 0.1016/S2213-8587(21)00045-0.
    [9]
    BUSCEMI S, CHIARELLO P, BUSCEMI C, et al. Characterization of metabolically healthy obese people and metabolically unhealthy normal-weight people in a general population cohort of the ABCD study[J]. J Diabetes Res, 2017, 2017: 9294038. DOI: 10.1155/2017/9294038.
    [10]
    OH H, JUN DW, LEE IH, et al. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2020, 52( 2): 371- 381. DOI: 10.1111/apt.15867.
    [11]
    MAK LY, HUI RW, LEE CH, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes[J]. Hepatology, 2023, 77( 2): 606- 618. DOI: 10.1002/hep.32716.
    [12]
    TAO J, ZHANG W, YUE H, et al. Prevalence of hepatitis B virus infection in Shenzhen, China, 2015-2018[J]. Sci Rep, 2019, 9( 1): 13948. DOI: 10.1038/s41598-019-50173-5.
    [13]
    LEE HW, KIM SU, PARK JY, et al. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy[J]. Liver Int, 2019, 39( 9): 1624- 1630. DOI: 10.1111/liv.14129.
    [14]
    MENA Á, PEDREIRA JD, CASTRO Á, et al. Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers[J]. J Gastroenterol Hepatol, 2014, 29( 1): 173- 178. DOI: 10.1111/jgh.12432.
    [15]
    BOCKMANN JH, KOHSAR M, MURRAY JM, et al. High rates of liver cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients with metabolic and cardiovascular comorbidities[J]. Microorganisms, 2021, 9( 5): 968. DOI: 10.3390/microorganisms9050968.
    [16]
    HUANG SC, SU TH, TSENG TC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B[J]. Hepatol Int, 2023, 17( 5): 1139- 1149. DOI: 10.1007/s12072-023-10545-6.
    [17]
    AMIRZADEGAN A, DAVOODI G, BOROUMAND MA, et al. Association between hepatitis B surface antibody seropositivity and coronary artery disease[J]. Indian J Med Sci, 2007, 61( 12): 648- 655.
    [18]
    KIM JT, PARK MS, NAM TS, et al. Multiple cerebral arterial stenosis associated with hepatitis B virus infection[J]. J Clin Neurol, 2011, 7( 1): 40- 42. DOI: 10.3988/jcn.2011.7.1.40.
    [19]
    JIANG D, CHEN C, LIU X, et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis[J]. Ann Transl Med, 2021, 9( 23): 1718. DOI: 10.21037/atm-21-3052.
    [20]
    WANG CC, CHENG PN, KAO JH. Systematic review: chronic viral hepatitis and metabolic derangement[J]. Aliment Pharmacol Ther, 2020, 51( 2): 216- 230. DOI: 10.1111/apt.15575.
    [21]
    VILAR-GOMEZ E, MARTINEZ-PEREZ Y, CALZADILLA-BERTOT L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149( 2): 367- 378. e5; quiz e14-15. DOI: 10.1053/j.gastro.2015.04.005.
    [22]
    YOUNOSSI ZM, COREY KE, LIM JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2021, 160( 3): 912- 918. DOI: 10.1053/j.gastro.2020.11.051.
    [23]
    CHANG FM, WANG YP, LANG HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study[J]. Hepatology, 2017, 66( 3): 896- 907. DOI: 10.1002/hep.29172.
    [24]
    SIMON TG, DUBERG AS, ALEMAN S, et al. Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide swedish population[J]. Ann Intern Med, 2019, 171( 5): 318- 327. DOI: 10.7326/M18-2753.
    [25]
    BHATTACHARJEE J, KIRBY M, SOFTIC S, et al. Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis[J]. Hepatol Commun, 2017, 1( 4): 299- 310. DOI: 10.1002/hep4.1041.
    [26]
    Professional Committee of Prevention and Treatment of Pharmaceutical Liver Injury of China Medical Biotechnology Association, Pharmaceutical Hepatology Group of Liver Disease Branch of Chinese Medical Association. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenterol, 2022, 27( 6): 341- 375. DOI: 10.3760/cma.j.cn501113-20230419-00176.

    中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2022, 27( 6): 341- 375. DOI: 10.3760/cma.j.cn501113-20230419-00176.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (357) PDF downloads(108) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return